Free Trial
NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Aeterna Zentaris logo
$2.50 -0.29 (-10.55%)
(As of 12/20/2024 ET)

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Key Stats

Today's Range
$2.50
$2.74
50-Day Range
$2.66
$5.72
52-Week Range
$3.96
$12.00
Volume
5,466 shs
Average Volume
7,305 shs
Market Capitalization
$4.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
CSCI:CA COSCIENS Biopharma Inc.
Chimerix Inc (CXF.BE)
See More Headlines

AEZS Stock Analysis - Frequently Asked Questions

Aeterna Zentaris' stock was trading at $7.44 at the beginning of 2024. Since then, AEZS stock has decreased by 66.4% and is now trading at $2.50.
View the best growth stocks for 2024 here
.

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($2.00) by $1.00. The biopharmaceutical company earned $0.60 million during the quarter, compared to analysts' expectations of $0.60 million. Aeterna Zentaris had a negative net margin of 760.32% and a negative trailing twelve-month return on equity of 83.45%.

Shares of Aeterna Zentaris reverse split on Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Tonix Pharmaceuticals (TNXP), Bausch Health Companies (BHC), Ford Motor (F), DarioHealth (DRIO), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and Meta Platforms (META).

Company Calendar

Last Earnings
11/04/2021
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AEZS
Employees
20
Year Founded
N/A

Profitability

Net Income
$-16,550,000.00
Net Margins
-760.32%
Pretax Margin
-760.28%

Debt

Sales & Book Value

Annual Sales
$2.37 million
Book Value
$14.99 per share

Miscellaneous

Free Float
1,791,000
Market Cap
$4.48 million
Optionable
No Data
Beta
1.55

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:AEZS) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners